The present disclosure relates to a process for manufacturing lanifibranor which comprises reacting N-(4-chloro-2-iodo-phenyl)-1,3-benzothiazole-6-sulfonamide with 5-hexynoic acid in the presence of a Palladium catalyst and a copper salt.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
05 - Pharmaceutical, veterinary and sanitary products
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical products; medicines for human purposes;
pharmaceutical preparations for veterinary use; chemical
preparations for pharmaceutical use; chemical preparations
for medical use; hygienic products for medical use;
pharmaceutical preparations and substances; dietetic
substances for medical use; plasters, material for
dressings; disinfectants; bath preparations for medical use;
vaccines; vitamins and vitamin preparations; these goods not
used in the field of living tissue, tissue regeneration or
3D printing. Transmission of information via electronic communication
networks; transmission of information by radio; transmission
of information by computer means; providing online
discussion forums for the transmission of messages between
computer users; transmission of information with respect to
pharmaceuticals, medicines and hygiene; these services not
used in the field of living tissue, tissue regeneration or
3D printing. Training and teaching services in the medical field;
organization of seminars and congresses in the field of
medicine; organization of congresses; publication of
magazines; publication of books; publication of medical
texts; training courses in the field of health;
entertainment; sporting and cultural activities; these
services not used in the field of living tissue, tissue
regeneration or 3D printing. Scientific and technological services; chemical research;
biological research; pharmaceutical research services;
design services; industrial analysis and research services;
scientific research for medical purposes; design and
development of computer hardware and software; computer
database design and development; tool design; design and
development of diagnostic apparatus; clinical trials;
scientific laboratory services; technical project studies;
cloud computing; software rental; carrying out clinical
trials for pharmaceutical products; scientific information
service; provision of information relating to scientific
technology; these services not used in the field of living
tissue, tissue regeneration or 3D printing. Medical services; pathological analyses for diagnostic and
therapeutic purposes; veterinary services; hospital
services; physical rehabilitation; hygiene and beauty care
for human beings; beauty care and hygiene services for
animals; advice with respect to health; pharmaceutical
advice; provision of medical information; consultation with
respect to pharmacy; health services; telemedicine services;
therapeutic services; medical diagnosis services; home
health care services; medical examination services for
individuals; telemedicine services; providing support in the
monitoring of patients receiving medical treatment; advice
with respect to health; medical information services;
medical monitoring of patients; medical information services
provided via the Internet and social networks; these
services not used in the field of living tissue, tissue
regeneration or 3D printing.
05 - Pharmaceutical, veterinary and sanitary products
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical products; medicines for human purposes;
pharmaceutical preparations for veterinary use; chemical
preparations for pharmaceutical use; chemical preparations
for medical use; hygienic products for medical use;
pharmaceutical preparations and substances; dietetic
substances for medical use; plasters, material for
dressings; disinfectants; bath preparations for medical use;
vaccines; vitamins and vitamin preparations; these goods not
used in the field of living tissue, tissue regeneration or
3D printing. Transmission of information via electronic communication
networks; transmission of information by radio; transmission
of information by computer means; providing online
discussion forums for the transmission of messages between
computer users; transmission of information with respect to
pharmaceuticals, medicines and hygiene; these services not
used in the field of living tissue, tissue regeneration or
3D printing. Training and teaching services in the medical field;
organization of seminars and congresses in the field of
medicine; organization of congresses; publication of
magazines; publication of books; publication of medical
texts; training courses in the field of health;
entertainment; sporting and cultural activities; these
services not used in the field of living tissue, tissue
regeneration or 3D printing. Scientific and technological services; chemical research;
biological research; pharmaceutical research services;
design services; industrial analysis and research services;
scientific research for medical purposes; design and
development of computer hardware and software; computer
database design and development; tool design; design and
development of diagnostic apparatus; clinical trials;
scientific laboratory services; technical project studies;
cloud computing; software rental; carrying out clinical
trials for pharmaceutical products; scientific information
service; provision of information relating to scientific
technology; these services not used in the field of living
tissue, tissue regeneration or 3D printing. Medical services; pathological analyses for diagnostic and
therapeutic purposes; veterinary services; hospital
services; physical rehabilitation; hygiene and beauty care
for human beings; beauty care and hygiene services for
animals; advice with respect to health; pharmaceutical
advice; provision of medical information; consultation with
respect to pharmacy; health services; telemedicine services;
therapeutic services; medical diagnosis services; home
health care services; medical examination services for
individuals; telemedicine services; providing support in the
monitoring of patients receiving medical treatment; advice
with respect to health; medical information services;
medical monitoring of patients; medical information services
provided via the Internet and social networks; these
services not used in the field of living tissue, tissue
regeneration or 3D printing.
The present disclosure is directed to a process for preparing lanifibranor comprising: a) reacting 5-chloroindole with t-butyl 4-bromobutyrate in a solvent; b) reacting the compound obtained in step a) with 1,3-benzothiazole-6-sulfonyl chloride in a solvent; and c) deprotecting the ester group of the compound obtained in step b).
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present disclosure is directed to a process for preparing lanifibranor comprising: a) reacting 5-chloroindole with 2-(4-bromobutoxy)tetrahydropyran in a solvent; b) reacting the compound obtained in step a) with 1,3-benzothiazole-6-sulfonyl chloride in a solvent; c) deprotecting the compound obtained in step b); d) oxidizing the compound obtained in step c).
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present disclosure relates to a drug combination and a method for the prevention and/or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1/GIP/glucagon triple receptor agonist.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
9.
NON-INVASIVE MONITORING OF NASH TREATMENT WITH LANIFIBRANOR
The present disclosure relates to a method of assessing the effectiveness of a treatment with lanifibranor in a patient with a liver disease, the method comprising: a) in vitro measuring levels of a combination of biomarkers consisting of CK18M65, Gamma Glutamyl Transferase, AST, insulin and urea, in a biological sample from the patient; b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).
in vitroin vitro measuring levels of a combination of biomarkers consisting of CK18M65, Gamma Glutamyl Transferase, AST, insulin and urea, in a biological sample from the patient; b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).
05 - Pharmaceutical, veterinary and sanitary products
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Produits pharmaceutiques; médicaments pour la médecine humaine; préparations pharmaceutiques à usage vétérinaire; préparations chimiques à usage pharmaceutique; préparations chimiques à usage médical; produits hygiéniques à usage médical; substances et préparations pharmaceutiques; substances diététiques à usage médical; emplâtres, matériel pour pansements; désinfectants; préparations pour le bain à usage médical; vaccins; vitamines et préparations de vitamines; ces produits n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D. (1) Transmission d'informations par réseaux de communications électroniques; transmission d'informations par radio; transmission d'informations par moyens informatiques; fourniture de forums de discussion en ligne pour la transmission de messages entre des utilisateurs d'ordinateurs; transmission d'informations en matière de produits pharmaceutiques, de médicaments et d'hygiène; ces services n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D.
(2) Services de formation et d'enseignement dans le domaine médical; organisation de séminaires et de congrès dans le domaine de la médecine; organisation de congrès; publication de magazines; publication de livres; publication de textes médicaux; services de cours de formation dans le domaine de la santé; divertissement; activités sportives et culturelles; ces services n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D.
(3) Services scientifiques et technologiques; recherches en chimie; recherche en biologie; services de recherches pharmaceutiques; services de conception; services d'analyses et de recherches industrielles; recherches scientifiques à des fins médicales; conception et développement de matériel informatique et de logiciels; conception et développement de bases de données informatiques; conception d'outils; conception et développement d'appareils de diagnostic; essais cliniques; services de laboratoires scientifiques; études de projets techniques; informatique en nuage; location de logiciels; réalisation d'essais cliniques pour des produits pharmaceutiques; service d'information scientifique; fourniture d'informations en matière de technologie scientifique; ces services n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D.
(4) Services médicaux; analyses pathologiques à des fins diagnostiques et thérapeutiques; services vétérinaires; services hospitaliers; rééducation physique; hygiène et soins de beauté pour êtres humains; services de soins de beauté et d'hygiène destinés aux animaux; conseils en matière de santé; conseil pharmaceutique; prestation d'informations médicales; consultation en matière de pharmacie; services de santé; services de télémédecine; services thérapeutiques; services de diagnostic médical; services de soins de santé à domicile; services d'examen médical pour particuliers; services de télémédecine; fourniture d'un soutien dans le suivi des patients recevant des traitements médicaux; conseils en matière de santé; services d'informations médicales; surveillance médicale de patients; services d'informations médicales fournis par le biais d'Internet et des réseaux sociaux; ces services n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D.
05 - Pharmaceutical, veterinary and sanitary products
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Pharmaceutical preparations for veterinary use; Chemical preparations for pharmaceutical purposes; Chemical preparations for medical purposes; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances; Dietetic substances adapted for medical use; Plasters, materials for dressings; Disinfectants; Bath preparations for medical purposes; Vaccines; Vitamins and vitamin preparations; None of the aforesaid goods being used in the field of living tissue, tissue regeneration or 3D printing. Transmission of information by electronic communications networks; Transfer of information by radio; Transmission of information via computer networks; Providing on-line forums for transmission of messages among computer users; Transmission of information relating to pharmaceuticals, medicine and hygiene; The aforesaid services not being used in the field of living tissue, tissue regeneration or 3D printing. Medical training and teaching; Organization of seminars and conventions in the field of medicine; Organising of congresses; Publication of magazines; Publication of books; Publication of medical texts; Instruction courses relating to health; Entertainment services; Sporting and cultural activities; The aforesaid services not being used in the field of living tissue, tissue regeneration or 3D printing. Scientific technological services; Chemical research; Biological research; Pharmaceutical research services; Design services; Industrial analysis and research services; Scientific research for medical purposes; Design and development of computer hardware and software; Database design and development; Design of instruments; Design and development of diagnostic apparatus; Clinical trials; Scientific laboratory services; Conducting technical project studies; Cloud computing; Rental of computer software; Conducting clinical trials for pharmaceutical products; Provision of scientific information; Providing science technology information; The aforesaid services not being used in the field of living tissue, tissue regeneration or 3D printing. Medical services; Pathological testing for diagnostic and treatment purposes; Animal healthcare services; Hospital services; Physical rehabilitation; Human hygiene and beauty care; Hygienic and beauty care for animals; Health counselling; Pharmaceutical advice; Providing medical information; Pharmacy advice; Medical services; Telemedicine services; Therapy services; Medical diagnostic services; Provision of health care services in domestic homes; Medical examination of individuals; Providing medical support in the monitoring of patients receiving medical treatments; Medical information; Monitoring of patients; Medical information provided via the Internet and social networks; The aforesaid services not being used in the field of living tissue, tissue regeneration or 3D printing.
05 - Pharmaceutical, veterinary and sanitary products
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Pharmaceutical preparations for veterinary use; Chemical preparations for pharmaceutical purposes; Chemical preparations for medical purposes; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances; Dietetic substances adapted for medical use; Plasters, materials for dressings; Disinfectants; Bath preparations for medical purposes; Vaccines; Vitamins and vitamin preparations; None of the aforesaid goods being used in the field of living tissue, tissue regeneration or 3D printing Transmission of information by electronic communications networks; Transfer of information by radio; Transmission of information via computer networks; Providing on-line forums for transmission of messages among computer users; Transmission of information relating to pharmaceuticals, medicines and hygiene; None of the aforesaid services being used in the field of living tissue, tissue regeneration or 3D printing Medical training and teaching in the medical field; Organization of seminars and conventions in the field of medicine; Congresses; Publication of magazines; Publication of books; Publication of medical texts; Instruction courses relating to health; Entertainment services; Sporting and cultural activities; None of the aforesaid services being used in the field of living tissue, tissue regeneration or 3D printing Scientific and technological services; Chemical research; Biological research; Pharmaceutical research services; Design services; Industrial analysis and research services; Scientific investigations for medical purposes; Design and development of computer hardware and software; Database design and development; Design of instruments; Design and development of diagnostic apparatus; Clinical trials; Scientific laboratory services; Studies of technical projects; Cloud computing; Rental of computer software; Conducting clinical trials for pharmaceutical products; Provision of scientific information; Providing science technology information; None of the aforesaid services being used in the field of living tissue, tissue regeneration or 3D printing Provision of medical services; Pathological testing for diagnostic and treatment purposes; Animal healthcare services; Hospital services; Physical rehabilitation; Human hygiene and beauty care for humans; Hygienic and beauty care for animals; Health counselling; Pharmaceutical advice; Providing medical information; Pharmacy advice; Medical services; Telemedicine services; Therapy services; Medical diagnostic services; Provision of health care services in domestic homes; Medical examination of individuals; Providing medical support in the monitoring of patients receiving medical treatments; Medical information; Monitoring of patients; Medical information services provided via the Internet and social networks; None of the aforesaid services being used in the field of living tissue, tissue regeneration or 3D printing
05 - Pharmaceutical, veterinary and sanitary products
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Pharmaceutical preparations for veterinary use; Chemical preparations for pharmaceutical purposes; Chemical preparations for medical purposes; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances; Dietetic substances adapted for medical use; Plasters, materials for dressings; Disinfectants; Bath preparations for medical purposes; Vaccines; Vitamins and vitamin preparations; None of the aforesaid goods being used in the field of living tissue, tissue regeneration or 3D printing Transmission of information by electronic communications networks; Transfer of information by radio; Transmission of information via computer networks; Providing on-line forums for transmission of messages among computer users; Transmission of information relating to pharmaceuticals, medicines and hygiene; None of the aforesaid services being used in the field of living tissue, tissue regeneration or 3D printing Medical training and teaching in the medical field; Organization of seminars and conventions in the field of medicine; Congresses; Publication of magazines; Publication of books; Publication of medical texts; Instruction courses relating to health; Entertainment services; Sporting and cultural activities; None of the aforesaid services being used in the field of living tissue, tissue regeneration or 3D printing Scientific and technological services; Chemical research; Biological research; Pharmaceutical research services; Design services; Industrial analysis and research services; Scientific investigations for medical purposes; Design and development of computer hardware and software; Database design and development; Design of instruments; Design and development of diagnostic apparatus; Clinical trials; Scientific laboratory services; Studies of technical projects; Cloud computing; Rental of computer software; Conducting clinical trials for pharmaceutical products; Provision of scientific information; Providing science technology information; None of the aforesaid services being used in the field of living tissue, tissue regeneration or 3D printing Provision of medical services; Pathological testing for diagnostic and treatment purposes; Animal healthcare services; Hospital services; Physical rehabilitation; Human hygiene and beauty care for humans; Hygienic and beauty care for animals; Health counselling; Pharmaceutical advice; Providing medical information; Pharmacy advice; Medical services; Telemedicine services; Therapy services; Medical diagnostic services; Provision of health care services in domestic homes; Medical examination of individuals; Providing medical support in the monitoring of patients receiving medical treatments; Medical information; Monitoring of patients; Medical information services provided via the Internet and social networks; None of the aforesaid services being used in the field of living tissue, tissue regeneration or 3D printing
05 - Pharmaceutical, veterinary and sanitary products
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Produits pharmaceutiques; médicaments pour la médecine humaine; préparations pharmaceutiques à usage vétérinaire; préparations chimiques à usage pharmaceutique; préparations chimiques à usage médical; produits hygiéniques à usage médical; substances et préparations pharmaceutiques; substances diététiques à usage médical; emplâtres, matériel pour pansements; désinfectants; préparations pour le bain à usage médical; vaccins; vitamines et préparations de vitamines; ces produits n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D. (1) Transmission d'informations par réseaux de communications électroniques; transmission d'informations par radio; transmission d'informations par moyens informatiques; fourniture de forums de discussion en ligne pour la transmission de messages entre des utilisateurs d'ordinateurs; transmission d'informations en matière de produits pharmaceutiques, de médicaments et d'hygiène; ces services n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D.
(2) Services de formation et d'enseignement dans le domaine médical; organisation de séminaires et de congrès dans le domaine de la médecine; organisation de congrès; publication de magazines; publication de livres; publication de textes médicaux; services de cours de formation dans le domaine de la santé; divertissement; activités sportives et culturelles; ces services n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D.
(3) Services scientifiques et technologiques; recherches en chimie; recherche en biologie; services de recherches pharmaceutiques; services de conception; services d'analyses et de recherches industrielles; recherches scientifiques à des fins médicales; conception et développement de matériel informatique et de logiciels; conception et développement de bases de données informatiques; conception d'outils; conception et développement d'appareils de diagnostic; essais cliniques; services de laboratoires scientifiques; études de projets techniques; informatique en nuage; location de logiciels; réalisation d'essais cliniques pour des produits pharmaceutiques; service d'information scientifique; fourniture d'informations en matière de technologie scientifique; ces services n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D.
(4) Services médicaux; analyses pathologiques à des fins diagnostiques et thérapeutiques; services vétérinaires; services hospitaliers; rééducation physique; hygiène et soins de beauté pour êtres humains; services de soins de beauté et d'hygiène destinés aux animaux; conseils en matière de santé; conseil pharmaceutique; prestation d'informations médicales; consultation en matière de pharmacie; services de santé; services de télémédecine; services thérapeutiques; services de diagnostic médical; services de soins de santé à domicile; services d'examen médical pour particuliers; services de télémédecine; fourniture d'un soutien dans le suivi des patients recevant des traitements médicaux; conseils en matière de santé; services d'informations médicales; surveillance médicale de patients; services d'informations médicales fournis par le biais d'Internet et des réseaux sociaux; ces services n'étant pas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D.
05 - Pharmaceutical, veterinary and sanitary products
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Pharmaceutical preparations for veterinary use; Chemical preparations for pharmaceutical purposes; Chemical preparations for medical purposes; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances; Dietetic substances adapted for medical use; Plasters, materials for dressings; Disinfectants; Bath preparations for medical purposes; Vaccines; Vitamins and vitamin preparations; None of the aforesaid goods being used in the field of living tissue, tissue regeneration or 3D printing. Transmission of information by electronic communications networks; Transfer of information by radio; Transmission of information via computer networks; Providing on-line forums for transmission of messages among computer users; Transmission of information relating to pharmaceuticals, medicine and hygiene; The aforesaid services not being used in the field of living tissue, tissue regeneration or 3D printing. Medical training and teaching; Organization of seminars and conventions in the field of medicine; Organising of congresses; Publication of magazines; Publication of books; Publication of medical texts; Instruction courses relating to health; Entertainment services; Sporting and cultural activities; The aforesaid services not being used in the field of living tissue, tissue regeneration or 3D printing. Scientific technological services; Chemical research; Biological research; Pharmaceutical research services; Design services; Industrial analysis and research services; Scientific research for medical purposes; Design and development of computer hardware and software; Database design and development; Design of instruments; Design and development of diagnostic apparatus; Clinical trials; Scientific laboratory services; Conducting technical project studies; Cloud computing; Rental of computer software; Conducting clinical trials for pharmaceutical products; Provision of scientific information; Providing science technology information; The aforesaid services not being used in the field of living tissue, tissue regeneration or 3D printing. Medical services; Pathological testing for diagnostic and treatment purposes; Animal healthcare services; Hospital services; Physical rehabilitation; Human hygiene and beauty care; Hygienic and beauty care for animals; Health counselling; Pharmaceutical advice; Providing medical information; Pharmacy advice; Medical services; Telemedicine services; Therapy services; Medical diagnostic services; Provision of health care services in domestic homes; Medical examination of individuals; Providing medical support in the monitoring of patients receiving medical treatments; Medical information; Monitoring of patients; Medical information provided via the Internet and social networks; The aforesaid services not being used in the field of living tissue, tissue regeneration or 3D printing.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; medicines for human purposes;
antibiotics; pharmaceutical preparations; chemical
preparations for medical or pharmaceutical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; medicines for human purposes;
antibiotics; pharmaceutical preparations; chemical
preparations for medical or pharmaceutical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; medicines for human purposes;
antibiotics; pharmaceutical preparations; chemical
preparations for medical or pharmaceutical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; medicines for human purposes;
antibiotics; pharmaceutical preparations; chemical
preparations for medical or pharmaceutical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; medicines for human purposes;
antibiotics; pharmaceutical preparations; chemical
preparations for medical or pharmaceutical use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Produits pharmaceutiques; médicaments pour la médecine humaine; antibiotiques; préparations pharmaceutiques; préparations chimiques à usage médical ou pharmaceutique.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Produits pharmaceutiques; médicaments pour la médecine humaine; antibiotiques; préparations pharmaceutiques; préparations chimiques à usage médical ou pharmaceutique.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Produits pharmaceutiques; médicaments pour la médecine humaine; antibiotiques; préparations pharmaceutiques; préparations chimiques à usage médical ou pharmaceutique.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Produits pharmaceutiques; médicaments pour la médecine humaine; antibiotiques; préparations pharmaceutiques; préparations chimiques à usage médical ou pharmaceutique.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Produits pharmaceutiques; médicaments pour la médecine humaine; antibiotiques; préparations pharmaceutiques; préparations chimiques à usage médical ou pharmaceutique.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products for the treatment of liver conditions, diseases and disorders; Medicines for human purposes for the treatment of liver conditions, diseases and disorders; Pharmaceutical preparations for the treatment of liver conditions, diseases and disorders; Chemical preparations for medical purposes, namely, for liver conditions, diseases and disorders; Chemical preparations for pharmaceutical purposes, namely, for liver conditions, diseases and disorders; Pharmaceutical products for the treatment of cardiovascular diseases; Medicines for human purposes for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular diseases; Chemical preparations for medical purposes, namely, for cardiovascular diseases; Chemical preparations for pharmaceutical purposes, namely, for cardiovascular diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products for the treatment of liver conditions, diseases and disorders; Medicines for human purposes for the treatment of liver conditions, diseases and disorders; Pharmaceutical preparations for the treatment of liver conditions, diseases and disorders; Chemical preparations for medical purposes, namely, for liver conditions, diseases and disorders; Chemical preparations for pharmaceutical purposes, namely, for liver conditions, diseases and disorders; Pharmaceutical products for the treatment of cardiovascular diseases; Medicines for human purposes for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular diseases; Chemical preparations for medical purposes, namely, for cardiovascular diseases; Chemical preparations for pharmaceutical purposes, namely, for cardiovascular diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products for the treatment of liver conditions, diseases and disorders; Medicines for human purposes for the treatment of liver conditions, diseases and disorders; Pharmaceutical preparations for the treatment of liver conditions, diseases and disorders; Chemical preparations for medical purposes, namely, for liver conditions, diseases and disorders; Chemical preparations for pharmaceutical purposes, namely, for liver conditions, diseases and disorders; Pharmaceutical products for the treatment of cardiovascular diseases; Medicines for human purposes for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular diseases; Chemical preparations for medical purposes, namely, for cardiovascular diseases; Chemical preparations for pharmaceutical purposes, namely, for cardiovascular diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products for the treatment of liver conditions, diseases and disorders; Medicines for human purposes for the treatment of liver conditions, diseases and disorders; Pharmaceutical preparations for the treatment of liver conditions, diseases and disorders; Chemical preparations for medical purposes, namely, for liver conditions, diseases and disorders; Chemical preparations for pharmaceutical purposes, namely, for liver conditions, diseases and disorders; Pharmaceutical products for the treatment of cardiovascular diseases; Medicines for human purposes for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular diseases; Chemical preparations for medical purposes, namely, for cardiovascular diseases; Chemical preparations for pharmaceutical purposes, namely, for cardiovascular diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products for the treatment of liver conditions, diseases and disorders; Medicines for human purposes for the treatment of liver conditions, diseases and disorders; Pharmaceutical preparations for the treatment of liver conditions, diseases and disorders; Chemical preparations for medical purposes, namely, for liver conditions, diseases and disorders; Chemical preparations for pharmaceutical purposes, namely, for liver conditions, diseases and disorders; Pharmaceutical products for the treatment of cardiovascular diseases; Medicines for human purposes for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular diseases; Chemical preparations for medical purposes, namely, for cardiovascular diseases; Chemical preparations for pharmaceutical purposes, namely, for cardiovascular diseases
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Antibiotics; Pharmaceutical preparations; Chemical preparations for medical purposes; Chemical preparations for pharmaceutical purposes. Pathological testing for diagnostic and treatment purposes; Health counselling; Pharmacy advice; Providing medical information; Provision of information relating to medicine; Medical information services provided via the Internet.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Antibiotics; Pharmaceutical preparations; Chemical preparations for medical purposes; Chemical preparations for pharmaceutical purposes. Pathological testing for diagnostic and treatment purposes; Health counselling; Pharmacy advice; Providing medical information; Provision of information relating to medicine; Medical information services provided via the Internet.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Antibiotics; Pharmaceutical preparations; Chemical preparations for medical purposes; Chemical preparations for pharmaceutical purposes. Pathological testing for diagnostic and treatment purposes; Health counselling; Pharmacy advice; Providing medical information; Provision of information relating to medicine; Medical information services provided via the Internet.
35.
TREATMENT OF A LIVER DISEASE IN PATIENTS WITH HEPATIC IMPAIRMENT
The present invention relates to methods for the treatment of liver disease in patients with hepatic impairment, in particular to methods for treating metabolic-associated steatohepatitis or non-alcoholic steatohepatitis in patients with hepatic impairment.
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Antibiotics; Pharmaceutical preparations; Chemical preparations for medical purposes; Chemical preparations for pharmaceutical purposes. Pathological testing for diagnostic and treatment purposes; Health counselling; Pharmacy advice; Providing medical information; Provision of information relating to medicine; Medical information services provided via the Internet.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Antibiotics; Pharmaceutical preparations; Chemical preparations for medical purposes; Chemical preparations for pharmaceutical purposes. Pathological testing for diagnostic and treatment purposes; Health counselling; Pharmacy advice; Providing medical information; Provision of information relating to medicine; Medical information services provided via the Internet.
38.
Methods and monitoring of treatment with lanifibranor
The present disclosure relates to methods for identifying a subject as eligible for treatment with lanifibranor, methods for treating a subject suffering from liver disease comprising administering lanifibranor to said subject and monitoring a subject's risk of experiencing a side effect caused by lanifibranor treatment.
The present invention relates to the use of sodium glucose transporter 2 (SGLT2) inhibitors for the prevention or delay of clinical complications of blood disorders, preferably anaemia or clinical complications of anaemia, in patients who having been treated, treated or planned to be treated with a PPAR agonist.
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
40.
METHODS AND MONITORING OF TREATMENT WITH LANIFIBRANOR
The present invention relates to methods for identifying a subject as eligible for treatment with lanifibranor, methods for treating a subject suffering from liver disease comprising administering lanifibranor to said subject and monitoring a subject's risk of experiencing a side effect caused by lanifibranor treatment.
The present invention relates to a deuterated derivative of lanifibranor of formula:
The present invention relates to a deuterated derivative of lanifibranor of formula:
The present invention relates to a deuterated derivative of lanifibranor of formula:
The compound is useful for the treatment of fibrotic diseases.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
42.
PYRROLOPYRAZINE COMPOUNDS AND THEIR USE IN THERAPY
11111 are as defined in the description, to pharmaceutical compositions containing said compounds, and to the use of said compounds as medicaments, in particular for the treatment or prevention of cancers or fibrosis related diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/428 - Thiazoles condensed with carbocyclic rings
44.
COMBINATION THERAPY FOR THE PREVENTION AND/OR THE TREATMENT OF A LIVER DISEASE
The present disclosure relates to a drug combination and a method for the prevention and/or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1/glucagon dual receptor agonist.
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
45.
COMBINATION THERAPY FOR THE PREVENTION AND/OR THE TREATMENT OF A LIVER DISEASE
The present disclosure relates to a drug combination and a method for the prevention and/or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1/GIP dual receptor agonist.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
46.
COMBINATION THERAPY FOR THE PREVENTION AND/OR THE TREATMENT OF A LIVER DISEASE
The present disclosure relates to a drug combination and a method for the prevention and/or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1/glucagon dual receptor agonist.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
47.
COMBINATION THERAPY FOR THE PREVENTION AND/OR THE TREATMENT OF A LIVER DISEASE
The present disclosure relates to a drug combination and a method for the prevention and/or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1/GIP dual receptor agonist.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure relates to a process for manufacturing lanifibranor which comprises reacting N-(4-chloro-2-iodo-phenyl)-1,3-benzothiazole-6-sulfonamide with 5-hexynoic acid in the presence of a Palladium catalyst and a copper salt.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/428 - Thiazoles condensed with carbocyclic rings
C07D 417/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; medicines for human medicine;
antibiotics; pharmaceutical preparations; chemical
preparations for medical or pharmaceutical use.
The present disclosure is directed to a process for preparing a compound of formula (I), which comprises a palladium-free coupling reaction between N-(4-chloro-2-iodo-phenyl)-1,3-benzothiazole-6-sulfonamide and methyl 5-hexynoate in the presence of a copper catalyst.
C07D 417/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Produits pharmaceutiques; médicaments pour la médecine humaine; antibiotiques; préparations pharmaceutiques; préparations chimiques à usage médical ou pharmaceutique.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceuticals; Medicines for human purposes; Antibiotics; Pharmaceutical preparations; Chemical preparations for medical or pharmaceutical purposes. Pathological testing for diagnostic and treatment purposes; Health counselling; Pharmacy advice; Providing medical information; Provision of information relating to medicine; Medical information services provided via the Internet.
55.
USE OF CK18M65, HYALURONIC ACID, FRUCTOSAMINE AND ALT FOR MONITORING OF LIVER DISEASE TREATMENT WITH LANIFIBRANOR
The present disclosure relates to a method of assessing the effectiveness of a treatment with lanifibranor in a patient with a liver disease, the method comprising:
a) in vitro measuring levels of a combination of biomarkers consisting of CK18M65, hyaluronic acid, fructosamine and ALT in a biological sample from the patient;
b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
58.
USE OF CK18M65, HYALURONIC ACID, FRUCTOSAMINE AND ALT FOR MONITORING OF LIVER DISEASE TREATMENT WITH LANIFIBRANOR
The present disclosure relates to a method of assessing the effectiveness of a treatment with lanifibranor in a patient with a liver disease, the method comprising: a) in vitro measuring levels of a combination of biomarkers consisting of CK18M65, hyaluronic acid, fructosamine and ALT in a biological sample from the patient; b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
60.
NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT
The present disclosure relates to a method for assessing the effectiveness of a treatment with lanifibranor in a patient with a liver disease, the method comprising:
a) in vitro measuring levels of a combination of biomarkers consisting of adiponectin, ferritin, MMP9 and transferrin in a biological sample from the patient; and
b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
61.
LANIFIBRANOR FOR USE IN THE TREATMENT OF SPLANCHNIC VASODILATATION IN A PATIENT WITH A LIVER CONDITION
The present invention relates to the use of lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof for the treatment of splanchnic vasodilatation in a patient with a liver condition.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
62.
USE OF ADIPONECTIN, FERRITIN, MMP9 AND TRANSFERRIN FOR MONITORING LIVER DISEASE TREATMENT WITH LANIFIBRANOR
in vitroin vitro measuring levels of a combination of biomarkers consisting of adiponectin, ferritin, MMP9 and transferrin in a biological sample from the patient; b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).
Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention is directed to a pharmaceutical composition useful for the treatment of liver fibrosis, the composition comprising from 55.0 wt% to 75.0 wt% of lanifibranor and from 25.0 wt% to 45.0 wt% of one or more excipients.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; Chemical preparations for medical or pharmaceutical purposes; Sanitary preparations for medical purposes; Substances for medical and pharmaceutical purposes; Dietetic substances adapted for medical use; Plasters, materials for dressings; Disinfectants; Bath preparations for medical purposes; Vaccines; vitamins, preparations made with vitamins; Pharmaceutical preparations; None of the aforesaid goods being used in the field of living tissue, tissue regeneration or 3D printing. Scientific research and analysis for medical purposes; Research services relating to health; Epidemiological research and Epidemiological studies; Genetic research and Genetic studies; Biochemistry research services; Bacteriological research; Chemical research; Chemical and biological analyses; Evaluations, assessments and research provided by engineers, doctors and physicists In the scientific and technological fields; preclinical and clinical research; Medical research; Research relating to biotechnology; Research laboratories; Pharmaceutical research and development and Pharmacokinetic research and development; Biological research; Research and development of new products for others; Conducting technical project studies; Engineering evaluations, estimates and research in the field of science and technology; Scientific research in the field of pharmacy; Pharmacological research and Pharmacological development; Implementation of clinical trials; Conducting clinical trials for pharmaceutical products and Conducting of clinical trials for pharmaceutical substances; None of the aforesaid services being related to the field of living tissue, tissue regeneration or 3D printing. Hospital services; Medical services; Therapy services; Medical services; Physical rehabilitation; Medical care; Medical analysis for the diagnosis and treatment of persons; Pharmaceutical services; Pharmacy advice; Consulting and information services Relating to pharmaceuticals and the pharmaceutical industry; Medical information; None of the aforesaid services being related to the field of living tissue, tissue regeneration or 3D printing.
68.
COMBINATION THERAPY FOR THE TREATMENT OF A LIVER DISEASE
The invention relates to a drug combination and a method for the treatment of a liver disease, the combination comprising lanifibranor and firsocostat.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
72.
COMBINATION THERAPY FOR THE TREATMENT OF A LIVER DISEASE
The invention relates to a drug combination and a method for the treatment of a liver disease, the combination comprising lanifibranor and firsocostat.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
73.
COMBINATION THERAPY FOR THE TREATMENT OF A LIVER DISEASE
The invention relates to a drug combination and a method for the treatment of a liver disease, the combination comprising lanifibranor and firsocostat.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
74.
Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer
The present invention relates to deuterated derivatives of lanifibranor, in particular for use in therapy, specifically in the treatment of fibrotic diseases.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
78.
NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA
The invention relates to compounds of formula:
The invention relates to compounds of formula:
The invention relates to compounds of formula:
wherein R1 to R7 are as defined in the description.
The invention relates to compounds of formula:
wherein R1 to R7 are as defined in the description.
These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.
C07D 275/06 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A compound of formula (I) wherein is a substituted or unsubstituted N-containing monocyclic, bicyclic or tricyclic heteroraryl. The compounds of the present invention can be used for treating a cancer where YAP is localized in the nucleus of tumor cells. The cancer may be lung cancer, thyroid cancer, ovarian cancer, colorectal cancer, prostate cancer, pancreas cancer, esophagus cancer, liver cancer, breast cancer or skin cancer. The cancer may be malignant mesothelioma.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07D 275/06 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 275/06 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention relates to deuterated derivatives of lanifibranor, in particular for use in therapy, specifically in the treatment of fibrotic diseases.
C07D 419/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations chimiques destinées à la fabrication de produits pharmaceutiques; ces produits n'étantpas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D
(2) Produits pharmaceutiques, nommément, des préparations pharmaceutiques pour le traitement de lafibrose, la mucoviscidose, des maladies lysosomales, des cancers, des maladies et des troubles hépatiques, desmaladies et des troubles rénaux, des maladies et des troubles métaboliques, du diabète, des maladies dusystème immunitaire, nommément, auto-immunes, des syndromes d'immunodéficience, des maladiesrespiratoires et du système respiratoire et des maladies génétiques rares et évolutives; ces produits n'étant pasutilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations chimiques destinées à la fabrication de produits pharmaceutiques; ces produits n'étantpas utilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D
(2) Produits pharmaceutiques, nommément, des préparations pharmaceutiques pour le traitement de lafibrose, la mucoviscidose, des maladies lysosomales, des cancers, des maladies et des troubles hépatiques, desmaladies et des troubles rénaux, des maladies et des troubles métaboliques, du diabète, des maladies dusystème immunitaire, nommément, auto-immunes, des syndromes d'immunodéficience, des maladiesrespiratoires et du système respiratoire et des maladies génétiques rares et évolutives ; ces produits n'étant pasutilisés dans le domaine du tissu vivant, de la régénération tissulaire ou de l'impression 3D
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary products, namely, pharmaceutical preparations for the treatment of fibrosis, lysosomal storage disorders, cancers, liver diseases, renal diseases, metabolic diseases, diabetes, auto immune diseases, and respiratory diseases; chemical preparations for medical or pharmaceutical use, namely, pharmaceutical preparations for the treatment of fibrosis, lysosomal storage disorders, cancers, liver diseases, renal diseases, metabolic diseases, diabetes, auto immune diseases, and respiratory diseases * ; these goods not being used in the field of living tissue, tissue regeneration or 3D printing *
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary products, namely, pharmaceutical preparations for the treatment of fibrosis, lysosomal storage disorders, cancers, liver diseases, renal diseases, metabolic diseases, diabetes, auto immune diseases, and respiratory diseases; chemical preparations for medical or pharmaceutical use, namely, pharmaceutical preparations for the treatment of fibrosis, lysosomal storage disorders, cancers, liver diseases, renal diseases, metabolic diseases, diabetes, auto immune diseases, and respiratory diseases * ; these goods not being used in the field of living tissue, tissue regeneration or 3D printing. *
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Printed matter, periodicals, magazines (periodicals),
posters, brochures, prospectuses, printed matter, forms,
newspapers, books, booklets, manuals, leaflets,
instructional and teaching material (except apparatus),
almanacs, albums, calendars, pens, pencils, postcards,
graphic representations, graphic reproductions, leaflets,
photographs; magazines, periodicals and other printed
matter in the field of health. Business management, business administration, business
management assistance for industrial and commercial
companies, business management and organization consulting,
business management consulting, professional business
consulting, business expertise, business estimates, business
information, business inquiries, computer file management,
business consultation, business research, statistical
development, market research, opinion polls, organization of
exhibitions for commercial or advertising purposes;
services for promoting cardiovascular disease education and
services for promoting a research program in the field of
health; promotion of clinical research in the field of
health; promotion of theses, dissertations, journals,
studies and works in the field of health; public relations;
advertising. Education, training and teaching services; education,
training services, practical training; educational tests,
organization and conducting of training workshops,
vocational guidance (advice relating to education or
training); entertainment; sporting and cultural activities;
information relating to education and entertainment;
leisure services; book publishing, book lending, video film
production, video tape editing, photographic services;
organization of competitions (education or entertainment);
correspondence courses; lessons given as part of seminars,
training courses, conferences and forums; organization and
conducting of colloquiums, conferences, conventions;
organization of exhibitions for cultural and educational
purposes; electronic publication of books and journals
online; online non-downloadable electronic publications
services; publication of texts (with the exception of
advertising texts); publication of books, newspapers,
magazines, brochures, periodicals and other texts and
printed matter; electronic desktop publishing; editing of
texts other than advertising texts; education services in
the field of health; the aforementioned services provided
in the context of promotion, to healthcare professionals, of
the residual risks of macro and micro-vascular events. Scientific research and analysis services for medical
purposes; research services in the field of health,
epidemiological studies and research, biological research,
research in biochemistry; bacteriology research, chemical
research, chemical, biological analysis; assessments,
estimates and research in the fields of science and
technology provided by engineers, physicians, physicists;
software development (design). Hospital services; medical services; medical educational
services; therapeutic services; health services; physical
rehabilitation services, medical care services.
89.
PPAR compounds for use in the treatment of fibrotic diseases
The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
The invention relates to compounds of formula (I):
6 are as defined in the description.
The compounds of formula (I) are inhibitors of the YAP/TAZ-TEAD interaction.
C07D 275/06 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
A61K 31/428 - Thiazoles condensed with carbocyclic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The invention relates to compounds of formula: wherein R1 to R7 are as defined in the description. These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 275/06 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
The present invention relates to the use of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-β-D-xylopyranoside in the treatment of a mucopolysaccharidosis such as type I mucopolysaccharidosis.
The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The compounds of formula (I) are inhibitors of the YAP/TAZ-TEAD interaction.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/428 - Thiazoles condensed with carbocyclic rings
C07D 275/06 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
The invention concerns the compounds of formula (l) in which W, X, Y, Z and Het are as defined in the description. The compounds of formula (I) are modulators of the NURR1 receptor.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
98.
NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS
The invention relates to compounds of formula (I), where R, R1, R2 n, A and Cy have the meanings indicated in the description. The compounds of formula (I) are Nurr-1 modulators.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4425 - Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
99.
USE OF ODIPARCIL IN THE TREATMENT OF A MUCOPOLYSACCHARIDOSIS
The present invention relates to the use of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-ß-D-xylopyranoside in the treatment of a mucopolysaccharidosis such as Maroteaux-Lamy syndrome.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
